Joseph Musaazi - Infectious Diseases

Author Information

J. Musaazi is affiliated with the Infectious Diseases Institute at Makerere University in Kampala, Uganda. With a focus on infectious diseases, Musaazi has contributed significantly to research in HIV, tuberculosis, and COVID-19, particularly in resource-limited settings. Their work often involves clinical trials and the development of community-based models for managing infectious diseases.

Research Contributions

J. Musaazi has made notable contributions to the field of infectious diseases, with research spanning various aspects of HIV treatment, including the efficacy and safety of different drug regimens for second-line treatment. Their work also addresses public health challenges such as multi-drug resistant tuberculosis and the management of non-severe COVID-19. Musaazi's research is characterized by a focus on practical and sustainable solutions in resource-limited environments, as evidenced by studies on patient-centered community-based models and the impact of nutritional and vitamin D status on disease outcomes.

Aliases

J. Musaazi is also known by the aliases J Musaazi and Joseph Musaazi. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Citation Count	514
H-index	12
Paper Count	70

Publications:

Nutritional status and its associated factors among HIV adolescents on second line regimen at Pediatric Infectious Diseases Clinic in Uganda

DOI: 10.1080/15381501.2021.2015503

Year: 2022

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

DOI: 10.1016/s2352-3018(22)00092-3

Year: 2022

Durability of Second-Line Anti-Retroviral Therapy in a Resource-Limited Setting: An 11-Year Analytical Cohort

DOI: 10.2139/ssrn.4057138

Year: 2022

Developing a patient-centered community-based model for management of multi-drug resistant tuberculosis in Uganda: a discrete choice experiment

DOI: 10.1186/s12913-021-07365-5

Year: 2022

Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis

DOI: 10.1371/journal.pone.0252762

Year: 2021

Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study

DOI: 10.1186/s12879-021-05967-2

Year: 2021

Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

DOI: 10.1186/s12879-021-06897-9

Year: 2021

Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial

DOI: 10.21203/RS.3.RS-506195/V1

Year: 2021

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

DOI: 10.1056/NEJMoa2101609

Year: 2021

Developing a Patient-Centered Community-Based Model for Management of Multi-Drug Resistant Tuberculosis in Uganda: A Mixed Methods Study

DOI: 10.21203/RS.3.RS-442837/V1

Year: 2021

How is Treatment Monitored?

How to Use Antibiotics Responsibly?

How is Colonization Detected?

How is West Nile Virus Transmitted?

What is a Pathogen?

How is Strep Throat Transmitted?

Can Inherited Immunity Be Enhanced?

What are the Long-Term Effects?

How Does Artemisinin Work?

What Role Does Technology Play in Personalized Medicine?

Partnered Content Networks

Relevant Topics